Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
How is it best to treat early rheumatoid arthritis patients?
Autore:
ODell, JR;
Indirizzi:
Univ Nebraska, Med Ctr, Sect Rheumatol & Immunol, Omaha, NE 68198 USA UnivNebraska Omaha NE USA 68198 Rheumatol & Immunol, Omaha, NE 68198 USA Univ Nebraska, Med Ctr, Dept Internal Med, Omaha, NE 68198 USA Univ Nebraska Omaha NE USA 68198 , Dept Internal Med, Omaha, NE 68198 USA
Titolo Testata:
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
fascicolo: 1, volume: 15, anno: 2001,
pagine: 125 - 137
SICI:
1521-6942(200103)15:1<125:HIIBTT>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
PLACEBO-CONTROLLED TRIAL; LONG-TERM MORTALITY; DOUBLE-BLIND; FOLLOW-UP; RADIOGRAPHIC PROGRESSION; MONOCLONAL-ANTIBODY; COMBINATION THERAPY; ANTIRHEUMATIC DRUGS; JOINT DESTRUCTION; FUSION PROTEIN;
Keywords:
rheumatoid arthritis; early; treatment; biologicals; minocycline; prognosis;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
79
Recensione:
Indirizzi per estratti:
Indirizzo: O'Dell, JR Univ Nebraska, Med Ctr, Sect Rheumatol & Immunol, Omaha, NE 68198 USA Univ Nebraska Omaha NE USA 68198 Immunol, Omaha, NE 68198 USA
Citazione:
J.R. O'Dell, "How is it best to treat early rheumatoid arthritis patients?", BEST PR R C, 15(1), 2001, pp. 125-137

Abstract

During the past decade, many important changes have occurred in the treatment of rheumatoid arthritis, perhaps the most important of which has been the realization that early diagnosis and early treatment are critical. This has challenged our health-care systems to make sure that patients with early arthritis have access to the appropriate physicians. Additionally, the last decade has also seen many new treatment options become available for patients with rheumatoid arthritis. These new options have included the use ofold drugs more effectively; the use of combinations of two or more disease-modifying anti-rheumatic drugs; new evidence to support the use of steroids: the resurrection of tetracyclines; the introduction of leflunomide; and,finally, the tumour necrosis factor inhibitors etanercept and infliximab. The availability of all these new options is clearly excellent news for patients with RA and their physicians. It is hoped that we will, in the next few years, better understand how most effectively to utilize these treatmentoptions for the optimal care of our patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 16:05:30